Biocon Limited is a global biopharmaceutical company changing patients’ lives by finding new and affordable ways to treat diabetes, cancer and autoimmune diseases. Our R&D focuses on prevention, alleviation and treatment and our medicines improve the lives of millions of patients in over 120 countries, by giving them access to life-saving therapies and relief.

From pipeline to production, from drug discovery to drug delivery, we bring differentiated, high-quality and affordable healthcare products to global communities.

Our 4 global businesses include generics, biosimilars, research services and novel biologics. They represent Biocon’s risk-balanced strategy, underpinned by agile network connections, a robust pipeline and a timely ‘emerging markets’ orientation. We have leveraged India’s value advantage of unmatched scientific talent and cost-competitive manufacturing to deliver scale, speed and quality. By making medicines more easily accessible for patients across the globe, we’re working towards achieving health equity.

Biocon has built large scale, world class manufacturing infrastructure to support its ambition of making global impact. We have one of India's largest bio-manufacturing facilities for insulins, monoclonal antibodies and devices. Our insulin manufacturing and R&D facility in Malaysia is the largest integrated insulins facility in Asia.

Biocon features on the prestigious U.S.-based Science magazine's annual Top Global Pharma and Biotech Employers list. We were ranked No. 8 in 2022, and have featured consistently on this list since our debut in 2012.

Biocon's passion to impact global health has enabled it to touch millions of patient lives. Our goal is to develop affordable blockbuster drugs with the potential to benefit a billion patients.